Catalent and Triphase Accelerator announce license agreement to advance SMARTag ADC to clinic

The proprietary SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, has announced that Triphase will obtain worldwide rights to further develop Catalentís proprietary CD22-4AP antibody drug conjugate (ADC), which has been developed by Catalentís wholly owned subsidiary, Redwood Bioscience, using its SMARTag technology platform.

Catalent will receive an upfront payment and has the potential to earn additional development and commercial milestone payments, plus a royalty on product sales. Triphase will also contract with Catalent for development, manufacturing and analytical services to support a fast path to clinic.

CD22-4AP is a novel, site-specific ADC targeting CD22, a B-cell restricted sialoglycoprotein that is an important modulator of B-cell signaling and survival, which is expressed on 90% of B-cell malignancies.

CD22 is a clinically validated ADC target with potential in Non-Hodgkinís Lymphoma (NHL) and Acute Lymphoid Leukemia (ALL).

Catalentís ADC, CD22-4AP, is a site-specific modified humanised antibody conjugated to a toxin payload using Catalentís proprietary Hydrazino-Pictet-Spengler (HIPS) chemistry and proprietary 4AP linker.

Preclinical data has shown that this optimisation of payload placement and linker composition, combined with the stability afforded by HIPS chemistry, leads to better tolerability and expanded therapeutic index.

Dr Mohit Trikha, Chief Scientific Officer, Executive Vice President and Head of R&D at Triphase, commented: 'Given our deep experience in investigating potential treatment for blood cancers and oncology clinical drug development, it is a logical progression for us to explore other approaches for other haematologic tumours. We believe in the potential of Catalentís SMARTag technology and look forward to advancing CD22-4AP to clinical proof of concept studies.'

'Triphase has demonstrated expertise and a track record in advancing preclinical oncology candidates to clinical proof of concept,' added Mike Riley, Catalent Biologicsí Vice President and General Manager. 'We look forward to leveraging Triphaseís expertise in combination with our proprietary SMARTag technology and supporting infrastructure to bring this potentially transformational treatment to patients.'

Companies